Helenie Kefalakes1,2, Bettina Budeus3, Andreas Walker1, Christoph Jochum2, Gudrun Hilgard2, Andreas Heinold4, Falko M Heinemann4, Guido Gerken2, Daniel Hoffmann3, Joerg Timm5. 1. Institute of Virology, University of Duisburg-Essen, University Hospital, Essen, Germany. 2. Department of Gastroenterology and Hepatology, University of Duisburg-Essen, University Hospital, Essen, Germany. 3. Research Group Bioinformatics, Centre for Medical Biotechnology, University of Duisburg-Essen, Essen, Germany. 4. Institute for Transfusion Medicine, University of Duisburg-Essen, University Hospital, Essen, Germany. 5. Institute for Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany.
Abstract
UNLABELLED: Activation of hepatitis B virus (HBV)-specific CD8 T cells by therapeutic vaccination may promote sustained control of viral replication by clearance of covalently closed circular DNA from infected hepatocytes. However, little is known about the exact targets of the CD8 T-cell response and whether HBV reproducibly evades CD8 T-cell immune pressure by mutation. The aim of this study was to address if HBV reproducibly selects substitutions in CD8 T-cell epitopes that functionally act as immune escape mutations. The HBV core gene was amplified and sequenced from 148 patients with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B loci) was determined. Residues under selection pressure in the presence of particular HLA class I alleles were identified by a statistical approach utilizing the novel analysis package SeqFeatR. With this approach we identified nine residues in HBV core under selection pressure in the presence of 10 different HLA class I alleles. Additional immunological experiments confirmed that seven of the residues were located inside epitopes targeted by patients with chronic HBV infection carrying the relevant HLA class I allele. Consistent with viral escape, the selected substitutions reproducibly impaired recognition by HBV-specific CD8 T cells. CONCLUSION: Viral sequence analysis allows identification of HLA class I-restricted epitopes under reproducible selection pressure in HBV core; the possibility of viral escape from CD8 T-cell immune pressure needs attention in the context of therapeutic vaccination against HBV.
UNLABELLED: Activation of hepatitis B virus (HBV)-specific CD8 T cells by therapeutic vaccination may promote sustained control of viral replication by clearance of covalently closed circular DNA from infected hepatocytes. However, little is known about the exact targets of the CD8 T-cell response and whether HBV reproducibly evades CD8 T-cell immune pressure by mutation. The aim of this study was to address if HBV reproducibly selects substitutions in CD8 T-cell epitopes that functionally act as immune escape mutations. The HBV core gene was amplified and sequenced from 148 patients with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B loci) was determined. Residues under selection pressure in the presence of particular HLA class I alleles were identified by a statistical approach utilizing the novel analysis package SeqFeatR. With this approach we identified nine residues in HBV core under selection pressure in the presence of 10 different HLA class I alleles. Additional immunological experiments confirmed that seven of the residues were located inside epitopes targeted by patients with chronic HBV infection carrying the relevant HLA class I allele. Consistent with viral escape, the selected substitutions reproducibly impaired recognition by HBV-specific CD8 T cells. CONCLUSION: Viral sequence analysis allows identification of HLA class I-restricted epitopes under reproducible selection pressure in HBV core; the possibility of viral escape from CD8 T-cell immune pressure needs attention in the context of therapeutic vaccination against HBV.
Authors: Hadi Karimzadeh; Muthamia M Kiraithe; Anna D Kosinska; Manuel Glaser; Melanie Fiedler; Valerie Oberhardt; Elahe Salimi Alizei; Maike Hofmann; Juk Yee Mok; Melanie Nguyen; Wim J E van Esch; Bettina Budeus; Jan Grabowski; Maria Homs; Antonella Olivero; Hossein Keyvani; Francisco Rodríguez-Frías; David Tabernero; Maria Buti; Andreas Heinold; Seyed Moayed Alavian; Tanja Bauer; Julian Schulze Zur Wiesch; Bijan Raziorrouh; Daniel Hoffmann; Antonina Smedile; Mario Rizzetto; Heiner Wedemeyer; Jörg Timm; Iris Antes; Christoph Neumann-Haefelin; Ulrike Protzer; Michael Roggendorf Journal: J Virol Date: 2018-06-13 Impact factor: 5.103
Authors: Sheila Lumley; Howard Noble; Martin J Hadley; Liz Callow; Amna Malik; Yi Yi Chua; Owen J Duffey; Natalia Grolmusova; Arvind Kumar; Samuel Ravenscroft; Jonathan I Spencer; Christoph Neumann-Haefelin; Robert Thimme; Monique Andersson; Paul Klenerman; Eleanor Barnes; Philippa C Matthews Journal: Wellcome Open Res Date: 2016-11-15
Authors: Philippa C Matthews; Jonathan M Carlson; Apostolos Beloukas; Amna Malik; Pieter Jooste; Anthony Ogwu; Roger Shapiro; Lynn Riddell; Fabian Chen; Graz Luzzi; Gerald Jesuthasan; Katie Jeffery; Nebojsa Jojic; Thumbi Ndung'u; Mary Carrington; Philip J R Goulder; Anna Maria Geretti; Paul Klenerman Journal: J Infect Dis Date: 2015-12-09 Impact factor: 5.226